Research and Markets: FirstImpact: FDA approval of Aubagio

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/8q59sw/firstimpact_fda) has announced the addition of the "FirstImpact: FDA approval of Aubagio" report to their offering.

The report presents the key insights gained from this major poll of neurologists. The research and analysis identifies the main clinical and commercial factors expected to influence the drug's positioning against current and upcoming rivals in the MS treatment algorithm and examines Aubagio's future prescribing trends.

The report also draws upon recent news coverage, analysis, and other market research undertaken, to provide background information about Aubagio, its development and its potential commercial positioning. The addition of key analyst opinion and consensus product forecasts for oral MS therapies provide a commercial perspective set against the views expressed by physicians.

The report and related data pack provides a comprehensive analysis of physicians' reactions for industry professionals who need to immediately understand the impact of breaking news.

Reasons To Buy

- Obtain insights into neurologists' positioning of Aubagio - Review the expected impact of Aubagio on physician prescribing - Understand neurologist perceptions of Aubagio versus other launched and pipeline oral therapies through poll results - Identify the most influential factors for Aubagio prescribing - Compare the efficacy and safety of Aubagio versus rival MS drugs - Identify the opportunities and challenges facing Aubagio - Review MS analysts' commercial expectations for Aubagio - Plan and align your investments in the future MS product market

Key Features

- Key insights gained from a poll of 298 US neurologists - Full written and graphical analysis of poll results - Data file providing line-by line response data - Review of the potential impact of Aubagio on physician prescribing - Predicted major MS trends and dynamics following Aubagio's launch - Expected positioning of Aubagio on the MS treatment algorithm - Key analyst quotes in respect of Aubagio's approval, set against analysis of physician response - Product sales forecasts for Aubagio vs rival MS drugs (BG-12, Gilenya, Laquinimod)

Key Topics Covered

See the article here:
Research and Markets: FirstImpact: FDA approval of Aubagio